Our molecular docking models investigating the interactions between validated targets (i.e., APP, BACE1 and GSK3B) and the 27 identified key chemical compounds found in YZD provides additional support for a role of YZD in the treatment of AD. Here, BACE1 is linked to Alzheimer disease.